by Virtus | Jun 28, 2026 | Early-Stage Respiratory Drug Development
Respiratory drug discovery is the foundation of every new treatment developed for asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, viral respiratory infections and other lung diseases. Before a medicine reaches clinical trials, researchers...
by Virtus | Jun 28, 2026 | Early-Stage Respiratory Drug Development
COPD drug development is one of the most active areas of respiratory research as scientists work to develop new therapies for chronic obstructive pulmonary disease. COPD affects hundreds of millions of people worldwide and remains a leading cause of illness and...
by Virtus | Jun 6, 2026 | Early-Stage Respiratory Drug Development
Asthma drug development plays a critical role in improving outcomes for millions of people living with asthma worldwide. Despite significant advances in treatment, asthma remains a complex and highly variable respiratory disease that continues to drive demand for...
by Virtus | Jun 6, 2026 | Respiratory Preclinical Research
Respiratory disease models are essential tools in preclinical respiratory research, allowing scientists to investigate disease mechanisms, evaluate therapeutic candidates and generate data that supports respiratory drug development. From asthma and COPD to viral...
by Virtus | Jun 6, 2026 | Early-Stage Respiratory Drug Development
Respiratory drug development is a complex process that transforms scientific discoveries into therapies for patients with respiratory diseases. From asthma and COPD to viral respiratory infections, developing new respiratory medicines requires a combination of...
